baeomycesic-acid and physcione

baeomycesic-acid has been researched along with physcione* in 1 studies

Other Studies

1 other study(ies) available for baeomycesic-acid and physcione

ArticleYear
Anti-proliferative lichen compounds with inhibitory activity on 12(S)-HETE production in human platelets.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2004, Volume: 11, Issue:7-8

    Several lichen compounds, i.e. lobaric acid (1), a beta-orcinol depsidone from Stereocaulon alpinum L., (+)-protolichesterinic acid (2), an aliphatic alpha-methylene-gamma-lactone from Cetraria islandica Laur. (Parmeliaceae), (+)-usnic acid (3), a dibenzofuran from Cladonia arbuscula (Wallr.) Rabenh. (Cladoniaceae), parietin (4), an anthraquinone from Xanthoria elegans (Link) Th. Fr. (Calaplacaceae) and baeomycesic acid (5), a beta-orcinol depside isolated from Thamnolia vermicularis (Sw.) Schaer. var. subuliformis (Ehrh.) Schaer. were tested for inhibitory activity on platelet-type 12(S)-lipoxygenase using a cell-based in vitro system in human platelets. Lobaric acid (1) and (+)-protolichesterinic acid (2) proved to be pronounced inhibitors of platelet-type 12(S)-lipoxygenase, whereas baeomycesic acid (5) showed only weak activity (inhibitory activity at a concentration of 100 microg/ml: (1) 93.4+/-6.62%, (2) 98,5+/-1.19%, 5 14.7+/-2.76%). Usnic acid (3) and parietin (4) were not active at this concentration. 1 and 2 showed a clear dose-response relationship in the range of 3.33-100 microg/ml. According to the calculated IC50 values the highest inhibitory activity was observed for the depsidone 1 (IC50 = 28.5 microM) followed by 2 (IC50 = 77.0 microM). The activity of 1 was comparable to that of the flavone baicalein, which is known as a selective 12(S)-lipoxygenase inhibitor (IC50 = 24.6 microM).

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; 4-Butyrolactone; Benzoates; Benzofurans; Blood Platelets; Depsides; Emodin; Humans; In Vitro Techniques; Lactones; Lichens; Lipoxygenase; Lipoxygenase Inhibitors; Molecular Structure; Resorcinols; Salicylates

2004